# Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

> **NCT00660101** · PHASE1,PHASE2 · UNKNOWN · sponsor: **AVAX Technologies** · enrollment: 34 (actual)

## Conditions studied

- Adenocarcinoma of the Ovary

## Interventions

- **BIOLOGICAL:** OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine

## Key facts

- **NCT ID:** NCT00660101
- **Lead sponsor:** AVAX Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-06
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660101, "Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00660101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*